NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. The company is headquartered in Beltsville, Maryland and currently employs 43 full-time employees. The company went IPO on 2019-05-09. The company focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidate, LNCB74, is designed as a B7-H4 targeted ADC to kill tumors. Its clinical oncology programs include NC410 and NC525. NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of, and decoy protein for, LAIR-1 that is designed to block immune suppression mediated by LAIR-1. NC525 is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia (AML), blast cells and leukemic stem cells.
Follow-Up Questions
Qui est le CEO de NextCure Inc ?
Mr. Michael Richman est le President de NextCure Inc, il a rejoint l'entreprise depuis 2015.
Quelle est la performance du prix de l'action NXTC ?
Le prix actuel de NXTC est de $5.66, il a increased de 0.45% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de NextCure Inc ?
NextCure Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de NextCure Inc ?
La capitalisation boursière actuelle de NextCure Inc est de $15.1M
Est-ce que NextCure Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 4 analystes ont établi des notations d'analystes pour NextCure Inc, y compris 2 achat fort, 5 achat, 2 maintien, 0 vente et 2 vente forte
